Lebrikizumab for Eczema
(ADmirable Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing lebrikizumab, a medication that reduces inflammation, in adolescents and adults with severe eczema and skin of color. The goal is to see if it is safe and effective for these patients.
Will I have to stop taking my current medications?
The trial requires that you stop taking certain medications before starting. You must stop using topical agents like corticosteroids and JAK inhibitors 2 weeks before the trial, and systemic immunosuppressive drugs and JAK inhibitors 4 weeks before the trial.
What data supports the effectiveness of the drug Lebrikizumab for eczema?
Is lebrikizumab safe for treating eczema?
Lebrikizumab has been shown to be generally safe in clinical trials for treating moderate-to-severe eczema, with most patients experiencing no significant side effects. Common mild side effects reported include conjunctivitis (eye inflammation), nasopharyngitis (cold-like symptoms), and headache.12345
How is the drug lebrikizumab different from other treatments for eczema?
Lebrikizumab is unique because it specifically targets interleukin-13 (IL-13), a protein involved in the inflammation process of eczema, offering a targeted approach to treatment. It is administered as an injection every four weeks, which may be more convenient compared to other treatments that require more frequent dosing.12456
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
This trial is for adults and adolescents (12 years and older) with moderate-to-severe atopic dermatitis, specifically those with skin of color (Fitzpatrick phototype IV-VI). Participants should have a history of inadequate response to topical treatments. Women must use effective contraception or remain abstinent, while men's requirements vary by location.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Lebrikizumab subcutaneously for 24 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Lebrikizumab
Lebrikizumab is already approved in European Union, United States, Canada for the following indications:
- Moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg
- Moderate-to-severe atopic dermatitis in adults and children 12 years and older who weigh at least 88 pounds (40 kg)
- Moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University